Study guide

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy

Key Takeaways Explain This Topic AI

The pharmacist-patient relationship is fundamentally fiduciary, imposing an uncompromised legal and ethical duty to place patient welfare above commercial, organizational, or personal interests.

Under provincial health privacy statutes (such as Ontario PHIPA, Alberta HIA, and BC PIPA), implied consent operates strictly within the direct 'circle of care,' while disclosing personal health information to insurers, employers, or police without a judicial warrant requires express consent or an imminent risk exemption.

Conscientious objection is a recognized professional right, but practitioners cannot abandon patients; they must promptly provide an objective, non-judgmental, and effective referral to ensure timely access to care.

Mandatory privacy breach reporting is legally required under PIPEDA and provincial health acts whenever a breach poses a real risk of significant harm (ROSH), necessitating immediate notification to affected individuals and the privacy commissioner.

Last updated: October 2026

Professional Ethics, Fiduciary Duty & Health Information Privacy

Pharmacy practice in Canada is anchored in a rigorous ethical and legal framework designed to safeguard patient well-being, protect personal health information, and maintain public trust in the profession. As accessible healthcare providers exercising expanded clinical decision-making, pharmacists must navigate complex ethical dilemmas, commercial pressures, and statutory privacy obligations with consistent moral integrity.

1. Core Ethical Principles in Canadian Pharmacy Practice

The National Association of Pharmacy Regulatory Authorities (NAPRA) and provincial pharmacy regulatory authorities (colleges) articulate core ethical principles that establish the standards of professional conduct. Every pharmacy practitioner is bound by these tenets across clinical, operational, and administrative decisions:

Beneficence: The moral obligation to act in the best interest of the patient, actively promoting their health, safety, and overall well-being. Examples include performing proactive medication therapy reviews, identifying drug therapy problems, and optimizing therapeutic regimens.

Non-Maleficence ( Primum non nocere ): The duty to do no harm. In pharmacy practice, this encompasses refusing to dispense unsafe doses, intercepting dangerous drug-drug interactions, preventing contraindications, and maintaining meticulous compounding safety standards.

Patient Autonomy: The recognition of a patient's right to self-determination, voluntary decision-making, and bodily integrity. Patients have the legal and ethical right to make informed decisions about their healthcare, including the right to accept or decline recommended pharmacotherapies without paternalistic coercion.

Veracity: The obligation to be truthful, transparent, and honest in all professional interactions. Pharmacists must provide candid and complete information regarding drug indications, risks, potential adverse effects, off-label uses, dispensing errors, and financial conflicts of interest.

Fidelity: The duty of loyalty, faithfulness, promise-keeping, and maintaining professional trust. This requires pharmacists to uphold confidentiality, respect the therapeutic relationship, and remain committed to the patient's ongoing care.

Justice: The ethical principle of fairness, equity, and impartiality in the distribution of healthcare resources. Pharmacists must treat all individuals with dignity and without discrimination based on race, ancestry, gender identity, sexual orientation, disability, socioeconomic status, or substance use disorder.

Ethical Decision-Making Framework

When ethical principles conflict—such as when patient autonomy (a patient refusing a vital antibiotic) clashes with beneficence (the pharmacist's desire to treat a severe infection)—practitioners should apply a structured ethical decision-making framework:

Identify the ethical problem: Clarify the conflicting principles and underlying moral issues.

Gather relevant facts: Collect objective clinical data, legal requirements, patient preferences, cultural contexts, and regulatory standards.

Identify stakeholders: Determine all parties affected by the decision (the patient, family/substitute decision-maker, healthcare team, and the public).

Evaluate alternatives: Formulate potential courses of action and assess their consistency with ethical principles, regulatory codes of ethics, and jurisprudence.

Select and execute the course of action: Implement the decision with empathy, professionalism, and thorough documentation.

Reflect on the outcome: Review the consequences of the decision to refine future ethical judgment.

2. The Fiduciary Relationship & Conflict of Interest Management

In Canadian law, the pharmacist-patient relationship is recognized as a fiduciary relationship . The Supreme Court of Canada has established that a fiduciary relationship arises when one party exercises discretionary power or specialized knowledge that affects the vital legal or practical interests of a vulnerable beneficiary who places trust in that professional ( Norberg v. Wynrib , McInerney v. MacDonald ).

Because patients lack specialized pharmaceutical knowledge and are in a vulnerable state seeking care, the pharmacist owes them a fiduciary duty of undivided loyalty. The pharmacist must subordinate personal, financial, and institutional self-interest to the best interests of the patient.

Types of Conflicts of Interest

A conflict of interest (COI) arises when a secondary interest (such as financial reward, professional prestige, or commercial quotas) has the potential to compromise or bias a pharmacist's professional judgment regarding a primary interest (patient care and safety):

Conflict Type Definition Clinical Example

Actual Conflict A real, existing situation where professional judgment is compromised by personal or financial gain. A pharmacist selects a higher-cost brand medication over an identical generic because the manufacturer provides direct financial kickbacks per unit dispensed.

Potential Conflict A foreseeable situation that could develop into an actual conflict if circumstances change. A pharmacist agrees to sit on a paid advisory board for a pharmaceutical company whose drug the pharmacist frequently evaluates for institutional formulary inclusion.

Perceived (Apparent) Conflict A situation where a reasonable, well-informed observer would conclude that professional judgment is likely biased, even if no actual bias occurs. A pharmacy accepts promotional merchandise, expensive dinners, or all-expenses-paid travel from a pharmaceutical sales representative promoting a novel GLP-1 agonist.

Commercial Pressures and Regulatory Boundaries

Provincial regulatory colleges enforce strict standards regarding commercial practices:

Gifts and Inducements: Pharmacists must not accept gifts, financial inducements, hospitality, or promotional items from pharmaceutical manufacturers or suppliers that could exert improper influence or create a perception of bias. Only modest educational items of nominal value directly relevant to practice are acceptable.

Dispensing Quotas and Commercial Incentives: Employment agreements or corporate policies that tie pharmacist compensation, bonuses, or performance reviews to dispensing volume, minor ailment prescription numbers, or medication review targets are strictly unacceptable where they risk compromising clinical care.

Preferred Provider Networks (PPNs) and Steering: Pharmacists must respect patient choice of pharmacy. Steered dispensing agreements or corporate incentives that coerce patients to utilize specific pharmacies must comply with provincial competition and anti-steering rules.

Important

When a conflict of interest cannot be avoided, the pharmacist must immediately and fully disclose the nature of the conflict to the patient and, where appropriate, recuse themselves from the decision-making process to preserve patient trust.

3. Conscientious Objection vs. Duty of Care (Patient Abandonment)

Canadian constitutional law (the Canadian Charter of Rights and Freedoms ) protects freedom of conscience and religion. In pharmacy practice, a conscientious objection occurs when a practitioner declines to provide a legal, health-related service or product because doing so conflicts with their deeply held moral, religious, or ethical beliefs.

Common clinical scenarios involving conscientious objection include:

Emergency Contraception: Dispensing levonorgestrel or ulipristal acetate.

Medical Assistance in Dying (MAID): Dispensing or preparing intravenous or oral MAID protocols (e.g., midazolam, propofol, rocuronium, bupivacaine).

Harm Reduction Supplies: Distributing naloxone kits or sterile injection equipment.

Reproductive Health: Dispensing mifepristone/misoprostol for medical termination of pregnancy.

Mandatory Obligations During Conscientious Objection

A pharmacist's right to conscientious objection is never absolute; it is legally and professionally subordinated to the patient's right to receive timely, non-discriminatory healthcare. Pharmacists cannot abandon the patient . Every provincial regulatory college requires adhering to four non-negotiable obligations: CONSCIENTIOUS OBJECTION PROTOCOL

1. PROMPT DECLARATION Inform pharmacy management/colleagues in advance and the patient

immediately upon presentation; never conceal or delay care.

  • │
  • ▼
  • 2. RESPECTFUL COMMUNICATION Communicate the objection professionally and objectively;

do NOT preach, judge, moralize, or attempt to dissuade the patient.

  • │
  • ▼
  • 3. EFFECTIVE REFERRAL Actively direct and assist the patient to an accessible, non-objecting

provider or pharmacy; do NOT leave the patient without recourse.

  • │
  • ▼
  • 4. CONTINUITY IN EMERGENCIES In an acute, life-threatening emergency where transfer causes critical delay,

the duty of non-maleficence/beneficence overrides personal objection.

Note

An "effective referral" means the objecting practitioner takes affirmative steps to connect the patient with an available, accessible colleague or facility capable of providing the service within a clinically appropriate timeframe. Simply handing a patient a phone book or telling them to "find someone else" does not satisfy professional standards.

4. Health Information Privacy: PIPEDA vs. Provincial Custodianship Acts

Protecting personal health information (PHI) is both an ethical cornerstone and a statutory mandate in Canada. Privacy legislation establishes rules for how health data is collected, used, disclosed, retained, and destroyed.

Legislative Framework

Privacy law in Canada operates on dual federal and provincial tracks:

PIPEDA (Personal Information Protection and Electronic Documents Act): The federal private-sector privacy statute. It applies to commercial activities across Canada, except in provinces that have enacted "substantially similar" provincial legislation covering the private sector or health information custodians.

Provincial Health Information Custodianship Acts: Provincial statutes tailored specifically to health data. Health practitioners acting as Health Information Custodians (HICs) —or "trustees" in some jurisdictions—are governed by their provincial health acts:

  • Ontario: Personal Health Information Protection Act (PHIPA, 2004)
  • Alberta: Health Information Act (HIA)

British Columbia: Personal Information Protection Act (PIPA) & Freedom of Information and Protection of Privacy Act (FIPPA) / E-Health Act

  • Saskatchewan: Health Information Protection Act (HIPA)
  • Manitoba: The Personal Health Information Act (PHIA)
  • Quebec: Act Respecting the Protection of Personal Information in the Private Sector

Statutory Dimension Federal PIPEDA Provincial Health Acts (e.g., PHIPA, HIA)

Primary Scope Commercial entities and federally regulated businesses. Health Information Custodians (HICs) delivering healthcare.

Key Focus Commercial transactions, general personal data. Personal health information (PHI), clinical records, diagnostic tests.

Regulatory Authority Privacy Commissioner of Canada (OPC). Provincial Information and Privacy Commissioners (e.g., IPC Ontario).

Application to Community Pharmacy Applies to retail retail transactions, commercial marketing, customer loyalty programs. Governs patient prescription profiles, clinical documentation, and interprofessional consultations.

  • 5. Circle of Care, Consent Models & Patient Directives
  • The Circle of Care & Implied Consent

The Circle of Care (or "care team") is a legal concept referring to the individuals and organizations directly providing healthcare to a specific patient. Within the circle of care, pharmacists may rely on implied consent to collect, use, and disclose personal health information, provided the following criteria are met:

The information is shared solely for the purpose of providing or assisting in providing healthcare to the patient.

The information shared is limited to the minimum necessary amount required for clinical care.

The patient has not expressly placed a restriction or "lockbox" on the record. INSIDE CIRCLE OF CARE OUTSIDE CIRCLE OF CARE

  • (Implied Consent for Healthcare) (Express Consent Required)
  • ┌──────────────────────────────────────────┐ ┌──────────────────────────────────────────┐
  • │ • Community Pharmacist │ │ • Life & Disability Insurance Companies │
  • │ • Primary Care Physician & Specialists │ │ • Employers & Human Resource Departments │
  • │ • Hospital Nurses & Clinical Staff │ │ • Police & Law Enforcement (w/o warrant) │
  • │ • Pharmacy Technicians under supervision │ │ • Family Members (w/o SDM authority) │
  • │ • Laboratory & Diagnostic Technicians │ │ • Commercial Marketing & Data Aggregators│
  • └──────────────────────────────────────────┘ └──────────────────────────────────────────┘
  • When Express Consent is Mandatory

Express (explicit) consent —which may be oral or written, though written is preferred for auditability—is legally mandated whenever personal health information is disclosed outside the circle of care, including:

Releasing prescription profiles to an employer or disability insurer.

Disclosing records to a patient's spouse, adult child, or parent (unless the parent is the legal substitute decision-maker for a minor lacking capacity).

Utilizing identifiable patient health data for commercial marketing, fundraising, or research without research ethics board (REB) waiver.

Transferring patient files to a third-party non-healthcare business.

Patient Lockbox (Consent Directives)

Under provincial statutes (such as Ontario PHIPA), a capable patient has the right to place a consent directive (commonly known as a lockbox ) on their personal health information. A lockbox restricts specific health data, or the entire record, from being shared with other healthcare providers in the circle of care.

Pharmacist Duty: The pharmacist must honor the lockbox and cannot disclose the restricted data to other practitioners without express patient consent.

Safety Disclosure: If withholding the locked information compromises patient safety, the pharmacist may disclose that information is being withheld (without revealing the locked content itself) or discuss the clinical risks with the patient to encourage voluntary disclosure.

Emergency Exception: A lockbox may be overridden without consent only in narrow emergency circumstances where disclosure is necessary to eliminate or reduce a significant risk of serious bodily harm or death.

  • 6. Privacy Breaches, Subpoenas & Law Enforcement Inquiries
  • Managing a Privacy Breach

A privacy breach occurs whenever personal health information is collected, used, accessed, disclosed, or disposed of without legal authorization. Examples include unauthorized electronic profile viewing ("snooping"), misdirected faxes/emails, lost unencrypted USB drives, ransomware attacks, or improper physical document shredding.

Under PIPEDA and provincial health acts, custodians must evaluate the breach under the Real Risk of Significant Harm (ROSH) standard: PRIVACY BREACH RESPONSE STEPS

1. CONTAINMENT Immediately halt unauthorized access, retrieve compromised records, revoke credentials,

and secure physical/digital perimeters.

  • │
  • ▼
  • 2. ASSESSMENT Evaluate the sensitivity of the data, likelihood of misuse, number of affected individuals,

and assess whether there is a Real Risk of Significant Harm (ROSH).

  • │
  • ▼
  • 3. NOTIFICATION Notify affected individuals promptly (to allow mitigation) AND report to the provincial

Information and Privacy Commissioner (IPC) whenever mandated by statute or ROSH.

  • │
  • ▼
  • 4. PREVENTION Conduct a root cause investigation, revise security policies, implement technical safeguards

(encryption, role-based access), and retrain staff.

Handling Police Inquiries and Subpoenas

A frequent PEBC exam trap involves law enforcement officers requesting patient pharmacy records during criminal investigations:

Informal Police Inquiries: A police badge does not grant automatic authority to access confidential health records. Pharmacists must not voluntarily disclose patient profiles, address information, or dispensing histories in response to informal verbal or written requests.

Judicial Authorization: Records may only be released to law enforcement upon presentation of a valid search warrant , court order , or subpoena signed by a judge or court registrar.

Emergency Disclosure Exception: Provincial acts permit disclosure without judicial warrant only if the pharmacist has reasonable grounds to believe that disclosure is immediately necessary to prevent an imminent risk of serious bodily harm or death to an individual or the public.

Statutory Mandatory Reporting Exceptions: Pharmacists must comply with explicit legislative reporting mandates that legally override confidentiality, such as provincial child protection acts (mandatory reporting of suspected child abuse or neglect), reporting impaired drivers to transportation ministries (where required), and public health reporting of designated communicable diseases.